Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
DSNKY DAIICHI SANKYO COMPANY LIMITED SPON ADR EA REPR 1 ORD JPY0.00 LEVEL I
32.760
-0.130-0.40%
YOY
Do not show
Hide blank lines
(Q2)2022/09/30(Q1)2022/06/30(FY)2022/03/31(Q4)2022/03/31
Total revenue
23.16% 327.48B 6.15% 280.32B 8.56% 1.04T 4.56% 233.93B
Operating revenue
23.16% 327.48B 6.15% 280.32B 8.56% 1.04T 4.56% 233.93B
Cost of revenue
-3.02% 84.77B -12.16% 74.8B 4.45% 353.33B 8.49% 88.83B
Gross profit
35.98% 242.71B 14.87% 205.52B 10.79% 691.56B 2.29% 145.1B
Operating expense
30.10% 181.51B 28.53% 171.14B 10.37% 618.54B 16.91% 195.84B
Selling and administrative expenses
34.30% 113.49B 21.81% 96.37B 7.57% 358.31B 0.90% 104.74B
-General and administrative expense
34.30% 113.49B 21.81% 96.37B 7.57% 358.31B 0.90% 104.74B
Research and development costs
37.64% 75.72B 38.68% 74.93B 14.46% 260.23B 43.00% 91.11B
Operating profit
57.03% 61.2B -24.88% 34.38B 14.47% 73.03B -97.70% -50.75B
Net non-operating interest income expense
630.40% 663M -481.56% -4.95B -96.45% 361M -1,359.70% -1.69B
Non-operating interest income
471.02% 3.37B -23.99% 1.56B -52.66% 6.11B 57.75% 1.23B
Non-operating interest expense
278.46% 2.71B 757.31% 6.51B 108.82% 5.75B 351.31% 2.92B
Other net income (expense)
Income before tax
59.03% 61.85B -37.50% 29.42B -0.82% 73.52B -105.82% -52.37B
Income tax
92.26% 22.39B -10.80% 10.56B 483.75% 6.54B 2.22% -25.03B
Net income
44.82% 39.46B -46.48% 18.85B -11.68% 66.97B -18,090.79% -27.35B
Net income continuous Operations
44.82% 39.46B -46.47% 18.85B -11.68% 66.97B -18,330.00% -27.35B
Minority interest income
0
Net income attributable to the parent company
44.82% 39.46B -46.48% 18.85B -11.83% 66.97B -18,090.79% -27.35B
Preferred stock dividends
Other preferred stock dividends
0 0 0 0
Net income attributable to common stockholders
44.82% 39.46B -46.48% 18.85B -11.83% 66.97B -18,090.79% -27.35B
Basic earnings per share
44.73% 20.58 -46.46% 9.84 -10.80% 34.94 -8,027.78% -14.27
Diluted earnings per share
44.86% 20.57 -46.46% 9.83 -10.74% 34.91 -8,494.12% -14.27
Dividend per share
0 0 -6.17% 25.4589 -10.22% 12.0901
Currency Unit
JPYJPYJPYJPY

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
CEO: Mr. Sunao Manabe
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist